Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Cbdv Compound
1. Cannabidivarol
2. 24274-48-4
3. Cbdv
4. Cbd-v
5. Gwp42006
6. I198vbv98i
7. Gwp-42006
8. 2-[(1r,6r)-3-methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl]-5-propylbenzene-1,3-diol
9. Cannabidivarin (cbdv)
10. (1'r,2'r)-5'-methyl-2'-(prop-1-en-2-yl)-4-propyl-1',2',3',4'-tetrahydro-[1,1'-biphenyl]-2,6-diol
11. Cannabidivarine
12. (1r-trans)-2-(3-methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl)-5-propyl-1,3-benzenediol
13. Unii-i198vbv98i
14. Schembl2759238
15. Chembl2387742
16. Chebi:182159
17. Dtxsid801019159
18. Cannabidivarin [nflis-drug]
19. Zinc5844413
20. Bdbm50532215
21. Akos030242161
22. Db14050
23. 1,3-benzenediol, 2-(3-methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl)-5-propyl-, (1r-trans)-
24. Ac-34111
25. Bc175204
26. C20217
27. Cannabidivarin (cbdv) 100 Microg/ml In Methanol
28. Cannabidivarin (cbdv) 1000 Microg/ml In Methanol
29. Resorcinol, 2-p-mentha-1,8-dien-3-yl-5-propyl-
30. 1,3-benzenediol, 2-((1r,6r)-3-methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl)-5-propyl-
31. 2-((1r,6r)-3-methyl-6-(prop-1-en-2-yl)cyclohex-2-en-1-yl)-5-propylbenzene-1,3-diol
| Molecular Weight | 286.4 g/mol |
|---|---|
| Molecular Formula | C19H26O2 |
| XLogP3 | 5.4 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 2 |
| Rotatable Bond Count | 4 |
| Exact Mass | 286.193280068 g/mol |
| Monoisotopic Mass | 286.193280068 g/mol |
| Topological Polar Surface Area | 40.5 Ų |
| Heavy Atom Count | 21 |
| Formal Charge | 0 |
| Complexity | 386 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 2 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Cannabidivarin does not currently have any FDA or Health Canada approved indications, however in October 2017 CBDV was given orphan designation by the European Medicines Agency for use in Rett Syndrome and again in February 2018 for treatment of Fragile X Syndrome.
Absorption
Like 9-THC, CBDV has low water solubility and poor oral bioavailability (~6% in humans), making oral administration an unfavourable method of delivery. Despite this, CBDV has relatively rapid absorption with peak concentrations seen around 2 h after oral administration in animal pharmacokinetic studies. Orally administered CBDV in mice was found to have a plasma Cmax of 0.47ug/mL and Tmax of 30 minutes, and a brain Cmax of 0.94ug/mL and Tmax of 60 minutes.
Volume of Distribution
Due to its lipophilicity, CBDV has been shown to cross the blood brain barrier.
Significant first-pass metabolism by the liver results in erratic absorption from the GI tract, low bioavailability, and unreliable pharmacokinetics.
Orally administered CBDV in mice was found to have a plasma elimination half life of 222 minutes, and a brain elimination half life of 204 minutes.
The anti-epileptic activity of CBD and CBDV is thought to be modulated by their effects on transient receptor potential cation channel subfamily V member 1 (TRPV1), also known as the capsaicin receptor, which is part of a large family of ion channels that are involved in the onset and progression of several types of epilepsy. CBD and CBDV have been shown to dose-dependently activate and then desensitize TRPV1 as well as TRPV2 and TRPA1 channels. Desensitization of these ion channels is a potential mechanism by which these molecules cause a reduction of neuronal hyperexcitability that contributes to epileptic activity and seizures. CBDV has also been shown to inhibit the activity of diacylglycerol (DAG) lipase-, the primary synthetic enzyme of the endocannabinoid, 2-arachidonoylglycerol (2-AG). The clinical implications of this are unclear however, as this interaction has not been shown to affect CBDV's anticonvulsant activity.
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]INTERMEDIATES SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ABOUT THIS PAGE
A Cannabidivarin manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Cannabidivarin, including repackagers and relabelers. The FDA regulates Cannabidivarin manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Cannabidivarin API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Cannabidivarin manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Cannabidivarin supplier is an individual or a company that provides Cannabidivarin active pharmaceutical ingredient (API) or Cannabidivarin finished formulations upon request. The Cannabidivarin suppliers may include Cannabidivarin API manufacturers, exporters, distributors and traders.
click here to find a list of Cannabidivarin suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
Cannabidivarin Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Cannabidivarin GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Cannabidivarin GMP manufacturer or Cannabidivarin GMP API supplier for your needs.
A Cannabidivarin CoA (Certificate of Analysis) is a formal document that attests to Cannabidivarin's compliance with Cannabidivarin specifications and serves as a tool for batch-level quality control.
Cannabidivarin CoA mostly includes findings from lab analyses of a specific batch. For each Cannabidivarin CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Cannabidivarin may be tested according to a variety of international standards, such as European Pharmacopoeia (Cannabidivarin EP), Cannabidivarin JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Cannabidivarin USP).
LOOKING FOR A SUPPLIER?
